AG
NBRV

Advisor Group’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Advisor Group’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-9
Closed -$5K – 5471
2019
Q1 		$5K Buy
+9
New +$4.91K ﹤0.01% 4727

Other funds holding NBRV

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Advisor Group's NBRV Position: Q2 2019 in Review

Advisor Group sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q2 2019, closing a stake of 9 shares — an estimated $5K sold.

Advisor Group first reported a position in NBRV in Q1 2019 and held it in 1 quarter. The position peaked at $5K in Q1 2019. 38 funds tracked by Wall St. Rank hold NBRV as of Q2 2019.

  • Advisor Group reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q2 2019 after selling out during the quarter.
  • Advisor Group sold 9 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q2 2019, an estimated $5K.
  • Advisor Group first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q1 2019 and held it in 1 quarter.
  • Advisor Group's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $5K in Q1 2019.
  • 38 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q2 2019.

Based on Advisor Group's 13F filing for Q2 2019, filed 31 Jul 2019.